Today: 7 February 2026
Subscribe
Browse Category

Pfizer News 16 December 2025 - 5 February 2026

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 February 2026
···
Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer shares rose 0.7% to $25.84 in Monday afternoon trading, tracking a broader U.S. stock rally ahead of major earnings and a Federal Reserve policy decision. Investors are watching for Pfizer’s Feb. 3 earnings and updates on its 2026 outlook, as the company faces falling COVID demand and looming patent expirations. Trading volume remained moderate, with no major company news released.
26 January 2026
····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
···
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer shares fell 0.6% to $25.12 in Tuesday afternoon trading after CEO Albert Bourla discussed plans to accelerate obesity drug trials at the J.P. Morgan Healthcare Conference. Bourla said Pfizer aims to launch 10 Phase 3 trials for its Metsera portfolio by 2026 but does not expect revenue growth before 2029. Investors await the Feb. 3 earnings report for updates on the obesity pipeline and guidance.
13 January 2026
···
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer shares closed up 1.1% at $25.18 on Friday, after leading U.S. drugmakers in January list-price hikes, including a 15% increase for its COVID vaccine Comirnaty. The stock remains below its 52-week high of $27.69. Investors await Pfizer’s Feb. 3 earnings update and monitor upcoming U.S. jobs and inflation data.
3 January 2026
····
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer shares slipped 0.4% to $24.90 after hours following a report the company will raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for its COVID vaccine Comirnaty. Most Pfizer increases are under 10%. U.S. stock markets were closed Thursday for New Year’s Day. Investors await Pfizer’s Feb. 3 results and 2026 outlook.
1 January 2026
···
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer shares fell 0.4% to $24.90 in after-hours trading after reports the company will lead U.S. drug list-price increases in 2026, including a 15% hike for its COVID vaccine. Healthcare data show Pfizer plans about 80 price increases, as drugmakers prepare for the annual January price reset under political scrutiny. Investors await further pricing updates and Pfizer’s February earnings call.
1 January 2026
···
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer shares edged up 0.1% to $25.03 Tuesday after TD Cowen reiterated a Hold rating and $30 price target, citing negative trends through 2030. The company projected 2026 revenue of $59.5 billion to $62.5 billion and warned of a “bumpy” period ahead as COVID demand fades and key patents expire. Shares have dropped over 50% since early 2023. Pfizer’s next earnings report is set for February 3.
30 December 2025
··
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer Inc. (NYSE: PFE) stock is spending Christmas Eve in the familiar “mid-$20s” zone — a level that has become a psychological battleground for investors trying to decide whether Pfizer is a high-yield value play, a turnaround story, or simply a “show-me” stock until growth returns. As of Dec. 24, 2025, Pfizer shares were trading around $25 in holiday-thinned markets, leaving the company with a market capitalization of roughly $142 billion and keeping the conversation laser-focused on one question: Can Pfizer rebuild durable growth after the COVID-era revenue boom — and ahead of a looming patent cliff and intensifying U.S.
24 December 2025
···
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (NYSE: PFE) ended Tuesday’s session (December 23, 2025) lower, then steadied in extended trading as investors digested a late-day safety headline tied to its hemophilia medicine Hympavzi (marstacimab). After-hours snapshot (as of 6:56 p.m. ET): PFE traded around $24.92, up about 0.16% in after-hours action, after closing the regular session at $24.88. Yahoo FinanceDuring Tuesday’s regular session, PFE ranged roughly between $24.84 and $25.34 with volume near 43.7 million shares. Where Pfizer Stock Closed on Dec. 23—and Why the Tape Looked “Holiday Thin” PFE closed down 1.31% at $24.88, snapping a two-day winning streak even as the broader market
24 December 2025
··
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Dec. 23, 2025 — Pfizer Inc. (NYSE: PFE) stock is ending 2025 in a familiar tug-of-war: a high-yield “value” profile on the one hand, and lingering uncertainty about the company’s post‑COVID growth engine on the other. Shares were trading around $25.15 on Tuesday, keeping the stock in the mid‑$20s range that’s defined much of its recent tape. Today’s news flow adds another variable for investors to price: a safety-related update tied to Pfizer’s hemophilia therapy Hympavzi, landing just as Wall Street digests Pfizer’s newly issued 2026 outlook and the company’s longer road back to growth. What’s moving Pfizer stock on
23 December 2025
···
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

As of Monday, December 22, 2025, Pfizer (NYSE: PFE) is once again at the center of a familiar market debate: is this a battered pharma giant destined to stay “dead money,” or a dividend-rich turnaround story that could surprise investors as its pipeline matures? The short-term reality is tough to miss. Pfizer has guided to flat-to-down revenue in 2026, with continued COVID-franchise erosion and an accelerating loss-of-exclusivity cycle. But the longer-term case—outlined in a wave of investor and analyst commentary this month—rests on whether Pfizer can execute in the two areas that matter most to its post-patent-cliff future: oncology and
22 December 2025
····
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer’s stock is ending 2025 in a familiar place: caught between near-term headwinds (shrinking COVID-era revenue, a growing patent cliff, and U.S. drug-pricing pressure) and a late-decade recovery narrative built around oncology, obesity, and pipeline execution. As of the latest available trade/close data around Dec. 20, Pfizer shares are near $25.19, modestly higher on the most recent session. Investing.com That price level matters because it frames the debate investors are having right now: Is PFE a high-yield “wait-it-out” turnaround, or a value trap until new launches and major clinical wins begin to offset upcoming losses of exclusivity? Below is a
21 December 2025
····
Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Inc. (NYSE: PFE) ended Thursday’s session essentially flat and stayed steady in after-hours trading, a sign that investors are still digesting the company’s newly issued 2026 outlook while watching a fast-evolving U.S. policy backdrop around drug pricing. As of early evening in New York, Pfizer shares were hovering around $25.05 in after-hours trading, after finishing the regular session at $25.04. Google Below is what moved the conversation around Pfizer today, what the latest forecasts imply, and the key items to monitor before the stock market opens Friday (Dec. 19, 2025). Pfizer stock after the bell: where PFE stands heading
19 December 2025
··
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. (NYSE: PFE) shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation. By late morning ET, Pfizer stock was trading around $25, down roughly 5% on the day after swinging between the mid-$26s and just under $25. The market’s message was clear: Pfizer’s transition away from pandemic-era revenue is still a work in progress, and 2026 is shaping up as another “bridge year” where lower COVID-19 sales and patent expirations pressure results—partly
16 December 2025
····
1 2

Stock Market Today

Go toTop